janus kinase (JAK) inhibitor for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 all comers meta-analysis
RECOVERY NCT04381936		RCT	baricitinib	standard of care	COVID 19 all comers	some concern	4148/4008	conclusif	demonstrated 13 % decrease in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 10 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
COVID-19 mild to moderate meta-analysis
Murugesan		RCT	tofacitinib	standard of care	COVID-19 mild to moderate	NA	50/50	inconclusive
3 studies excluded by filtering options (0 RCT / 3 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 all comers meta-analysis

COVID-19 mild to moderate meta-analysis